Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

ItalyBack to Italy

Clinical trials in Saronno – page 213

2 862 clinical trials in Saronno, Italy across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

ItalyOur site in ItalyStudi-Clinici.it(opens in a new tab)
Saronno at a glance
2 862
clinical trials
  • Research sites1
Type of trial
Recruitment status
Quick filters

2 862 trials in Saronno

Open in trial search

Rheumatoid arthritis

Not recruiting

Study Comparing Upadacitinib and Adalimumab for Adults with Moderate to Severe Rheumatoid Arthritis Not Responding to a Single TNF Inhibitor

Registered drug
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Adalimumab
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Cholangiocarcinoma

Not recruiting

Study of Futibatinib for Patients with Advanced Cholangiocarcinoma with FGFR2 Fusions or Rearrangements

InvestigationalNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Futibatinib
  • Sponsor:Taiho Oncology Inc.

Plasma cell myeloma

Not recruiting

Study on the Safety and Effects of Forimtamig, Tocilizumab, and Daratumumab in Patients with Relapsed or Refractory Multiple Myeloma

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Carfilzomib
  • Sponsor:F. Hoffmann-La Roche AG

Non-small cell lung cancer metastatic

Not recruiting

Study Comparing Pembrolizumab Alone and with Sacituzumab Govitecan for Patients with Metastatic Non-Small Cell Lung Cancer with High PD-L1 Levels

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Pembrolizumab
  • Sponsor:Merck Sharp & Dohme LLC

Cerebral palsy+5

Not recruiting

Study on Valbenazine for Treating Dyskinesia in Children and Adults with Cerebral Palsy

Investigational
Countries:ItalyItaly
  • Participants:0–17 years · 18–64 years · 65+ years
  • Sponsor:Neurocrine Biosciences Inc.

Leiomyosarcoma metastatic

Not recruiting

Study of Lurbinectedin and Doxorubicin for First-line Treatment in Patients with Metastatic Leiomyosarcoma

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Filgrastim
  • Sponsor:Pharma Mar S.A.

Glycogen storage disease type II

Not recruiting

Study on the Safety and Efficacy of Cipaglucosidase Alfa and Miglustat for Children with Late-onset Pompe Disease

InvestigationalNo placebo
Countries:ItalyItaly
  • Participants:0–17 years
  • Substances:Miglustat
  • Sponsor:Amicus Therapeutics Inc.

Juvenile spondyloarthritis+2

Not recruiting

Study of Ixekizumab and Adalimumab for Children with Juvenile Idiopathic Arthritis, Including Enthesitis-related Arthritis and Juvenile Psoriatic Arthritis

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:0–17 years
  • Substances:Adalimumab
  • Sponsor:Eli Lilly & Co.

Crohn's disease

Not recruiting

Study on the Long-Term Safety and Effectiveness of Upadacitinib for Patients with Moderate to Severe Crohn's Disease

Investigational
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Upadacitinib
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Acute lymphocytic leukaemia recurrent

Not recruiting

Study of Inotuzumab Ozogamicin Alone and with Drug Combination for Children with Relapsed or Refractory Acute Lymphoblastic Leukemia

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:0–17 years
  • Substances:Inotuzumab Ozogamicin
  • Sponsor:Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC)

Squamous cell carcinoma of head and neck

Not recruiting

Study of Tislelizumab, Surzebiclimab, and LBL-007 for Patients with Recurrent or Metastatic Head and Neck Cancer

InvestigationalNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:LBL-007
  • Sponsor:BeOne Medicines AG

Acute myocardial infarction

Not recruiting

Study to Test BI 765845 for Patients with Heart Attack

Registered drug
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:BI 765845
  • Sponsor:Boehringer Ingelheim Espana S.A.

Other cities in Italy

The busiest research cities in the country

All 230 cities in Italy

Clinical research in Saronno

What the registry says about research in the country

01 Respiratory Oncology

Multiple clinical trials focusing on non-small cell lung cancer (NSCLC) treatments, including studies evaluating novel therapeutic approaches for patients with specific genetic mutations.

  • MET deregulation therapy assessment
  • Second-line combination treatments
  • EGFR mutation targeting

Research emphasizes personalized treatment strategies for advanced and metastatic disease states.

02 Women's Oncology

Comprehensive studies addressing breast cancer and gynecological malignancies, with focus on treatment timing and maintenance therapies.

  • Endocrine-responsive breast cancer treatment
  • Ovarian cancer maintenance therapy
  • BRCA wild-type cancer management

Investigations aim to optimize treatment sequences and improve patient outcomes.

03 Specialized Oncology & Cardiology

Innovative research in renal cell carcinoma treatment and cardiac conditions, particularly focusing on novel therapeutic approaches.

  • Metastatic renal cancer therapy
  • Atrial fibrillation management
  • Targeted combination therapies

Studies evaluate both oncological interventions and cardiovascular treatments for high-risk patients.

Back to ItalyAll countries
Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.